INTRODUCTION
============

T-acute lymphoblastic leukemia (T-ALL) is characterized by the proliferation of T-lineage lymphoid blasts but represents a heterogeneous group of neoplastic cells. Although 80--95% of adults and 95% of pediatric patients with ALL achieve complete remission (CR) at the end of induction therapy, a substantial proportion of T-ALL patients are inadequately treated and experience disease relapse, while others may be over-treated because of the inability to individualize clinical treatment \[[@B1][@B2][@B3]\].

There are several classifications of T-ALL according to immunophenotypic analysis and T-cell receptor (*TCR*) genetic analysis \[[@B4][@B5][@B6]\]. The European Group for the Immunological Characterization of Leukemias (EGIL) defined four developmental stages in T-ALL \[[@B5]\]: prothymocytic (pro-T), prethymocytic (pre-T), cortical, and medullary T-ALL. Pro-T and pre-T-ALLs represent immature immunophenotypes, and cortical and medullary T-ALLs represent mature immunophenotypes. Patients with cortical or medullary T-ALL immunophenotypes have higher CR rates than those with pro-T or pre-T-ALL immunophenotypes \[[@B4]\]. Until recently, it has been difficult to make an accurate diagnosis or classify T-ALL into precise subgroups \[[@B2]\]. Nevertheless, the differences in maturation arrest during T-cell development may be of prognostic significance to T-ALL patients \[[@B4][@B7]\]. Alternatively, T-ALL can be classified according to *TCR* rearrangements, since the *TCRβ*, *TCRγ*, and *TCRδ* configurations show distinct gene expression signatures related to maturation arrest at different stages of T-cell differentiation, which may better reflect T-cell development \[[@B8]\].

Chromosomal abnormalities and common genetic rearrangements related to T-ALL have not been clearly identified \[[@B9][@B10]\]. *TCR* clonality detection rates in European pediatric and adult T-ALL patients have been found to be 95% \[[@B1][@B11]\] and 84% \[[@B12]\], respectively. In particular, a *TCR* gene can be identified in most pediatric cases of T-ALL, and the *TCR* gene rearrangement can be considered a marker for minimal residual disease (MRD). Among the several methods to detect *TCR* clonality status, the multiplex PCR-based fragment analysis technique is currently available and provides information on the TCR repertoire at a previously inaccessible level of analysis \[[@B13]\].

We evaluated the frequency of *TCR* rearrangements in the Korean T-ALL patients using fragment analysis. After clonality testing, we investigated the association between the clinicopathologic findings and clonality status, with age and immunophenotype as the core variables. Overall survival and event-free survival (EFS) were also investigated, and the correlation between survival and *TCR* clonality was assessed. Finally, we examined the feasibility of *TCR* rearrangement as an MRD marker using follow-up specimens. The limit of detection (LOD) and clonal stability at relapse were evaluated to determine the MRD sensitivity and stability during disease progression.

METHODS
=======

Patients and specimens
----------------------

A total of 51 adult and pediatric patients diagnosed as having T-ALL between 2002 and 2012 from three tertiary hospitals, Pusan National University Hospital (N=20, Busan), Pusan National University Yangsan Hospital (N=12, Yangsan), and the National Cancer Center (N=19, Goyang), in Korea were included in this retrospective study. The study was approved by the Institutional Review Board of the Pusan National University Yangsan Hospital (No. 05-2014-061). Informed consent was obtained from all the patients.

Among the archival specimens, bone marrow (BM) aspirates obtained at initial diagnosis and at the end of induction chemotherapy (days 23--45) from each patient were used for this study. Baseline and clinicopathologic characteristics, including age, immunophenotype, cytogenetics, and clinical outcomes, were obtained from reviews of electronic medical records at the three hospitals in December 2016.

The patients were arbitrarily divided into two age groups: children (N=16, \<12 years) and adolescents/adults (N=35; ≥12 years) \[[@B14]\]. EFS was defined as survival with no objective evidence of disease progression or relapse. Immunophenotypic analysis was performed using fresh specimens in the clinical laboratories of each participating hospital. Patients were classified into immunophenotypic subgroups based on the EGIL criteria \[[@B5]\]: pro-T (CD7+, CD2−, and/or CD34+, but CD1− or sCD3−), pre-T (CD7+, CD2+, and/or CD34+, but CD1− or sCD3−), cortical T (CD34− and CD4+CD8+ double positivity), or medullary T (sCD3+, CD34−, and either CD4+ or CD8+) subgroups.

The BM specimens and baseline and clinicopathologic information were sent to Pusan National University Yangsan Hospital. Genomic DNA was extracted from the archival BM specimens using a QIAmp DNA Mini kit (Qiagen, Hilden, Germany), according to the manufacturer\'s protocol, at this hospital. The purity and concentration of DNA were verified using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA).

*TCR* rearrangements using fragment analysis
--------------------------------------------

Fragment analysis was performed using IdentiClone *TCR* Gene Clonality Assay (InVivoScribe Technologies, San Diego, CA, USA) at Pusan National University Hospital for two years from October 2015 to March 2016. Analysis of *TCR* arrangements included three reactions that targeted *TCR*β (Vβ-Jβ1/2.2/2.6/2.7 for *TCR*βA, Vβ-Jβ2.1/2.3/2.4/2.5 for *TCR*βB, and Dβ-Jβ for *TCR*βC), two reactions that targeted *TCR*γ (Vγ1-8/Vγ10-Jγ1/2/P1/P2 for *TCR*γA and Vγ9/Vγ11-Jγ1/2/P1/P2 for *TCR*γB), and one reaction that targeted *TCR*δ (Vδ--Jδ). The fragments as PCR products were analyzed on an automated capillary electrophoresis system (ABI 3,130, Applied Biosystems, Foster City, CA, USA), and the sizes of the PCR products were determined using GeneMapper v4.0 (Applied Biosystems). All electropherograms were examined by at least two experts in fragment analysis.

For the initial diagnostic specimens, fragment analysis for *TCRβ*, *TCRγ*, and *TCRδ* rearrangements was simultaneously conducted. Rearrangements were interpreted as clonotypes according to the EuroClonality/BIOMED-2 guidelines \[[@B6][@B13]\]. The criteria for defining a positive peak were the display of discrete bands by the products within the expected size range and the largest peak being at least three times higher than the third largest peak in the polyclonal background. To evaluate its feasibility as an MRD marker, *TCR* rearrangements were also examined using fragment analysis at the end of induction chemotherapy. MRD is detected based on an initially identified leukemia-specific clonotype, which is the same fragment with a unique length on an electropherogram. Because of BM hypoplasia at the end of induction chemotherapy, the DNA content obtained was not sufficient for analysis in 14 specimens. In addition, three patients without *TCR* clonality at initial diagnosis were excluded from this assay; therefore, the *TCR* rearrangements were investigated in BM specimens from only 34 patients at the end of induction chemotherapy.

To investigate the possibility for MRD monitoring, LOD and clonal stability at relapse were also evaluated. Initial diagnostic specimens from three T-ALL patients were used for assessing the LOD of this technology. The blasts in the BM of the three patients were 98.8%, 82.7%, and 55.9%, respectively. Serial dilutions of the three selected specimens that were positive for *TCR* rearrangement were prepared, ranging from 10^-1^ to 10^-4^ of normal peripheral blood mononuclear cells. All assays were performed in duplicate. We performed fragment analysis for four randomly selected patients from Pusan National University Hospital who relapsed within two years of the initial diagnosis, and compared the clonotypes at the initial diagnosis with those at relapse to investigate clonal stability.

Statistical analysis
--------------------

Categorical data were summarized as counts and percentages, and continuous data were summarized as medians with interquartile range (IQR). Categorical data were analyzed using the chi-square test, and continuous data were analyzed using the Student\'s t-test or Mann-Whitney U test as appropriate. Frequencies of *TCR* rearrangement and the distribution of immunophenotypes based on the EGIL classification of *TCR* clonality subgroups were compared between children and adolescent/adult T-ALL patients using Student\'s t-test, Pearson\'s chi-squared test, Fisher\'s exact test (when expected cell counts were \<5), one-way ANOVA, or Mann-Whitney U test. Kaplan-Meier and log-rank tests were used to compare overall survival or EFS in different groups. *P*\<0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 22.0 (SPSS Inc., Chicago, IL, USA).

RESULTS
=======

Frequency of *TCR* rearrangements
---------------------------------

A total of 62 clonal PCR products of different *TCR* rearrangements were identified through fragment analysis in 38 (74.5%) of the 51 T-ALL patients at diagnosis. Fragment analysis identified at least one clonal rearrangement in the 38 specimens, using the three-target (*TCRβ*, *TCRγ*, and *TCRδ*) sets. Among the 51 patients, monoclonal rearrangements were found in 18 patients for *TCRβ*, 31 patients for *TCRγ*, and 14 patients for *TCRδ*. Two or more *TCR* rearrangements occurring in a single specimen were identified for 22 patients (43.1%). Among the 38 patients, the median and IQR of rearrangements per patient were 2.0 and 1.0, respectively. Depending on the serial dilution for assessing LOD, this method detected *TCR* rearrangements at an LOD above 10^-2^ (sensitivity 1%).

Association of *TCR* clonality with patient characteristics
-----------------------------------------------------------

The clinical characteristics of patients with or without *TCR* clonality at diagnosis are presented in [Table 1](#T1){ref-type="table"}. *TCR* clonality was significantly related to age and immunophenotype but not to sex, BM blast counts, CR, or survival. Children with T-ALL (15/16, 93.8%) showed a higher frequency of clonality than adolescents/adults (23/35, 65.7%). Clonality was associated with age (*P*=0.033). Further analyses according to the three age groups, children, adolescents, and adults, are described in [Supplemental Data Tables S1](#S1){ref-type="supplementary-material"}, [S2](#S2){ref-type="supplementary-material"}, [S3](#S3){ref-type="supplementary-material"}.

To investigate the association between clonal *TCR* rearrangement and T-cell development stage, patients were assigned to the following T-cell development subgroups based on the EGIL criteria 2 ([Table 2](#T2){ref-type="table"}): the pro-/pre-T subgroup (N=19) as an immature subtype and the cortical/medullary T-cell subgroup (N=32) as the mature subtype. Since the number of patients in each of the four subgroups was relatively small, the immature and mature subtypes were clustered.

Overall, *TCR* clonality was associated with the immunophenotypic subgroups (*P*=0.049, [Table 2](#T2){ref-type="table"}). Among the patients with *TCR* clonality (N=38), 11 had the immature phenotype, whereas among the patients without *TCR* clonality (N=13), three patients had cortical-T and two had medullary T-ALL mature phenotypes. Although the association between immunophenotype and *TCR* clonality was significant, neither immunophenotype nor *TCR* clonality influenced overall survival or EFS (*P*=0.561 and *P*=0.449, respectively).

Clinical significance of *TCR* clonality at the end of induction chemotherapy
-----------------------------------------------------------------------------

Among the 34 tested patients, 30 were interpreted to be in morphological remission (\<5% blasts on the all nucleated cells) and cytogenetic remission; however, four patients showed persistent leukemic blasts. A total of 15 clonotypes (five *TCRβ*, eight *TCRγ*, and two *TCRδ* rearrangements) were detected in 14 (41.2%) patients. Among these 14 patients with *TCR* clonality, three showed persistent leukemic blasts on BM aspirates, and 11 had no residual leukemic cells. One persistent patient did not exhibit clonality and thus was among the 20 patients whose *TCR* rearrangements were not detected. The 11 patients showing morphological remission were regarded as having MRD based on the presence of *TCR* rearrangements.

After excluding the four patients with morphological persistence, the association of clinical characteristics with *TCR* clonality was assessed for a total of 30 patients. As shown in [Table 3](#T3){ref-type="table"}, no significant difference was observed in BM blast count, BM cellularity, and relapse or death within two yrs between the two groups. Patients with MRD detected at the end of induction chemotherapy had relatively lower survival; however, this finding was not significant (*P*=0.416). Among the eight relapsed patients, only three showed early positive MRD results ([Table 3](#T3){ref-type="table"}).

Stability of *TCR* clonality at relapse
---------------------------------------

To investigate the stability of *TCR* clonality, clinicopathologic characteristics at initial diagnosis and relapse were compared in four randomly selected relapsed patients at Pusan National University Hospital. Three of the four relapsed patients were positive for *TCR* clonality at relapse and had received allogenic stem cell transplantation before relapse; all three of these relapsed patients had clonotypes different from those detected at initial diagnosis. Patient 3 relapsed within four months after transplantation; however, the immunophenotype and *TCR* clonality were different from those at the initial diagnosis, although the initial chromosomal abnormality was retained. Patient 4 relapsed at seven months after allogenic stem cell transplantation ([Table 4](#T4){ref-type="table"}).

DISCUSSION
==========

The overall frequency of *TCRβ*, *TCRγ*, and *TCRδ* rearrangements was 74.5% in Korean patients with T-ALL at initial diagnosis. Korean children with T-ALL showed a higher frequency of clonality (93.8%) than adolescents/adults (65.7%). The frequency of *TCR* clonality in European pediatric T-ALL patients (95%) was similar to that of the Korean children T-ALL group \[[@B1]\]; however, the frequency of *TCR* clonality in European adult T-ALL patients is 84% \[[@B12]\] and higher than that of Korean adolescent/adult T-ALL patients. Age distribution might be a main factor contributing to the difference in frequencies in Korean and European patients. Two previous studies conducted in Taiwan and Korea included both children and adult patients, and detected *TCR* clonality in 59--67% of the patients \[[@B13][@B15]\]. Compared with that of European adult T-ALL patients, this study showed relatively low detection rates of patients suggesting that ethnic diversity may also contribute to the low frequency of *TCR* rearrangements in Asians.

Using the EGIL and TCR classification systems, Bene et al. \[[@B5]\] demonstrated that approximately a half of the T-ALL patients could be assigned to relatively comparable developmental stages. However, neither the EGIL nor the TCR subgroups predicted clinical outcomes in our study. Nevertheless, the TCR classification system may be more applicable to pediatric T-ALL cases than the EGIL classification system. We used complementary immunophenotypic and *TCR* genotypic analysis to confirm and extend these data. In a previous study \[[@B4]\], 4%, 4%, 39%, and 10% of adult T-ALL patients were classified with the pro-T, pre-T, cortical T, and medullary immunophenotypes, respectively (age range: 14--52 years; median: 26.6 years). Similar results were observed in the present study. Furthermore, the association between immunophenotype and *TCR* clonality was confirmed, wherein immature groups had lower frequencies of *TCR* rearrangement (*P*=0.049).

The overall proportion of patients exhibiting *TCR* clonality was similar to those previously reported for T-ALL patients through real-time quantitative PCR (RQ-PCR) or sequence analysis \[[@B16][@B17]\]. Using RQ-PCR, Flohr et al. \[[@B16]\] detected two or more instances of clonality in 88% of 422 children with T-ALL and at least one clonal *TCR* rearrangement in 93% of the patients. Therefore, either technique appears to be suitable for detecting T-ALL clonality at diagnosis.

The LOD of this method in our study was 1%, indicating that this assay is not sufficiently sensitive to detect MRD. Research has suggested that detection of the post-therapy MRD burden (\>10^-4^) in BM aspirates or detection of *TCR* clonality can be a more powerful prognostic marker for subsequent relapse than typically used markers, such as age, white blood cell count at diagnosis, and cytogenetic alterations \[[@B17][@B18]\]. However, in our study, *TCR* clonality at diagnosis or at the end of induction chemotherapy was not useful for predicting overall survival and EFS, such as death within two yrs and relapse within two years.

From the perspective of stability, three of the four relapsed patients showed clonal evolution. Although fragment analysis was not suitable for assessing MRD due to the low LOD, it can be used to sensitively detect newly proliferating leukemic clones when using all three clonality combinations. The immunophenotypes and *TCR* clonotypes of Patient 3 ([Table 4](#T4){ref-type="table"}) were different at diagnosis and relapse, but the karyotype was identical. The discrepancy between the same cytogenetic findings and clonal evolutions by *TCR* rearrangement and immunophenotyping in this relapsed patient might be due to the low detection sensitivity of conventional karyotyping. Indeed, translocations, such as t(1;14)(p32;q11), cryptic interstitial deletion at 1p32 (*TAL1*), and deletion of 9p, are often not detected by karyotyping in T-ALL but are identified through only molecular genetic analysis \[[@B19][@B20]\]. Therefore, the *TCR* rearrangement assay is useful for surveillance, but its ability to predict early relapse in the CR state is limited due to clonal evolution.

The current clinical strategies to assess MRD rely on next-generation sequencing (NGS) and RQ-PCR-based methods using patient-specific primers \[[@B9][@B17][@B21]\]. In our study, the relapsed patients showed different clonotypes, suggesting clonal evolution compared with the state at initial diagnosis. Compared with RQ-PCR, NGS has the advantage of detecting clonal evolution during the course of disease, thus abrogating the risk of obtaining false-negative results. Therefore, NGS-based *TCR* rearrangement will likely become a part of routine practice for the diagnosis and follow-up of patients with hematological neoplasms \[[@B22][@B23]\].

The low frequency of *TCR* rearrangement in Korean adolescent/adult patients might also be due to the quality of archived specimens. Because this study was a retrospective study, specimen quality was the most important limitation of the study. The qualty of archived specimens depends on the storage period and conditions. Therefore, low specimen quality could have contributed to the low detection rate. Conducting fragment analysis at diagnosis with fresh, good-quality specimens could reveal the exact frequency of *TCR* rearrangement in Korean T-ALL patients. Other major limitations of this study were the very small number of patients, prolonged storage of specimens, and low sensitivity of the detection method. Further studies, including a larger number of patients and highly sensitive methods may help improve the clinical diagnosis and subsequent MRD monitoring of T-ALL patients.

In summary, the *TCR* clonal frequencies in children (\<12 years) and adolescent/adult patients (≥12 years) with T-ALL in Korea were found to be 93.8% and 65.7%, respectively. Although a higher frequency of *TCR* rearrangements was noted in children and in patients with a cortical or medullary immunophenotype, no significant association was found between *TCR* clonality and clinical outcomes such as EFS. Moreover, clonal evolution in *TCR* rearrangement was noted between diagnosis and relapse. This phenomenon should be explored in future studies involving a large and diverse set of patients, using a high-throughput technique.
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SUPPLEMENTARY MATERIALS
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###### Supplemental Data Table S1

Baseline characteristics of T-ALL patients according to three age groups

###### Supplemental Data Table S2

Frequency of *TCR* clonality detected using fragment analysis at initial diagnosis according to three age groups of T-ALL patients

###### Supplemental Data Table S3

Characteristics of T-ALL patients with morphological remission according to age groups at the end of induction chemotherapy

###### Baseline characteristics of T-ALL patients according to *TCR* clonality

![](alm-39-125-i001)

                                         Total (N=51)        No clonality (N=13)   Clonality (N=38)   *P*^\*^
  -------------------------------------- ------------------- --------------------- ------------------ ---------
  Sex                                                                                                 0.699
   Male, N (%)                           33 (64.7)           9 (69.2)              24 (63.2)          
   Female, N (%)                         18 (35.3)           4 (30.7)              14 (36.8)          
  Age (yr), median (IQR)                 18.0 (9.2--33.1)    19.0 (15.8--33.1)     15.6 (6.8--33.1)   0.473
  Age group                                                                                           0.033
   Children (\< 12 yr), N (%)            16 (31.4)           1 (7.7)               15 (39.5)          
   Adolescents/Adults (≥ 12 yr), N (%)   35 (68.6)           12 (92.3)             23 (60.5)          
  Immunophenotype^†^                                                                                  0.049
   Pro-/Pre-T, N (%)                     19 (37.3)           8 (61.5)              11 (28.9)          
   Cortical/Medullary T, N (%)           32 (62.7)           5 (38.5)              27 (71.1)          
  BM blasts (%), median (IQR)            83.1 (61.0--93.0)   80.0 (56.1--90.1)     83.1(60.5--97.3)   0.672
  CR after induction CTx, N (%)          39 (76.5)           9 (69.2)              30 (78.9)          0.393
  Death within two years, N (%)          20 (39.2)           6 (46.2)              14 (36.8)          0.414
  Relapse within two years, N (%)        15 (29.4)           4 (30.8)              11 (28)            0.691

^\*^Calculated using Student\'s t-test, Pearson\'s chi-squared test, or Mann-Whitney U test; ^†^Patients were classified into immunophenotypic subgroups based on the criteria of the European Group for the Immunological Characterization of Leukemias and assigned to the pro-/pre-T subgroup as an immature subtype and the cortical/medullary T-cell subgroup as a mature subtype.

Abbreviations: T-ALL, T-acute lymphoblastic leukemia; *TCR*, T-cell receptor; IQR, interquartile range; Pro-T, prothymocytic; Pre-T, prethymocytic; BM, bone marrow; CR, complete remission; CTx, chemotherapy.

###### Frequency of *TCR* clonality using fragment analysis at initial diagnosis according to the immunophenotype subgroups^\*^ of T-ALL patients

![](alm-39-125-i002)

                         Total (N = 51)   Pro-T (N = 8)   Pre-T (N = 11)   Cortical T-ALL (N = 23)   Medullary T-ALL (N = 9)
  ---------------------- ---------------- --------------- ---------------- ------------------------- -------------------------
  None                   13 (25.5)        4 (50.0)        4 (36.4)         3 (13.0)                  2 (22.2)
  *TCRβ*                 2 (3.9)                                           1 (4.3)                   1 (11.1)
  *TCRγ*                 11 (21.6)                        2 (18.2)         5 (21.7)                  4 (44.4)
  *TCRδ*                 5 (9.8)          1 (12.5)        3 (27.3)                                   1 (11.1)
  *TCRβ*+*TCRγ*          11 (21.6)                                         11 (47.8)                 
  *TCRβ*+*TCRδ*          0 (0.0)                                                                     
  *TCRγ*+*TCRδ*          4 (7.8)          2 (25.0)        1 (9.1)                                    1 (11.1)
  *TCRβ*+*TCRγ*+*TCRδ*   5 (9.8)          1 (12.5)        1 (9.1)          3 (13.0)                  
  At least one *TCR*     38 (74.5)        4 (50.0)        7 (63.6)         20 (87.0)                 7 (77.8)

Values are presented as N (%).

^\*^T-ALL patients were stratified into different stages of intrathymic differentiation according to the antigens expressed: pro-T (CD7+, CD2−, and/or CD34+, but CD1− or sCD3−), pre-T (CD7+, CD2+, and/or CD34+, but CD1− or sCD3−), cortical T (CD34− and CD4+CD8+ double positivity), or medullary T (sCD3+, CD34−, and either CD4+ or CD8+) subgroups based on the criteria of the European Group for the Immunological Characterization of Leukemias. The pro-thymocyte and pre-thymocyte stages are double-negative for CD4 and CD8, and the cortical thymocyte stage shows a double-positive (CD4+CD8+) phenotype. The medullary T stage expresses only either CD4 or CD8.

Abbreviations: *TCR*, T-cell receptor; T-ALL, T-acute lymphoblastic leukemia; Pro-T, prothymocyte.

###### Characteristics of T-ALL patients with morphological remission according to *TCR* clonality at the end of induction chemotherapy

![](alm-39-125-i003)

                                         Total (N = 30)^\*^   No clonality (N = 19)   Clonality (N = 11)   *P*^†^
  -------------------------------------- -------------------- ----------------------- -------------------- --------
  Age (yr), median (IQR)                 15.1 (5.7--22.5)     13.2 (6.2--33.0)        16.5 (4.0--22.0)     0.523
  Age group                                                                                                0.442
   Children (\<12 yr), N (%)             13 (43.3)            9 (47.4)                4 (36.4)             
   Adolescents/Adults (≥ 12 yr), N (%)   17 (56.7)            10 (52.6)               7 (63.6)             
  BM blasts (%), median (IQR)            0.4 (0.2--0.6)       0.4 (0.2--0.5)          0.2 (0.2--1.2)       0.689
  Death within two years, N (%)          11 (35.5)            6 (31.6)                5 (45.5)             0.643
  Relapse within two years, N (%)        6 (19.4)             4 (21.1)                2 (18.2)             0.724

^\*^Among 34 patients who were tested with fragment analysis at the end of induction chemotherapy, four persistently leukemic patients were excluded; ^†^Student\'s t-test, Pearson\'s chi-squared test, or Mann-Whitney U test was used for statistical test.

Abbreviations: *TCR*, T-cell receptor; T-ALL, T-acute lymphoblastic leukemia; IQR, interquartile range; BM, bone marrow; T-ALL, T-acute lymphoblastic leukemia.

###### Clinicopathologic characteristics of the four relapsed patients at Pusan National University Hospital, Busan, Korea

![](alm-39-125-i004)

  No. case               Diagnosis                                                                                   Day 29                Relapse                                                                     
  ---------------------- ------------------------------------------------------------------------------------------- --------------------- --------------------------------------------------------------------------- ----------------------
  1                      Age (yr)                                                                                    20                                                                                                21 (9 months later)
  WBC count (×10^9^/L)   430.00                                                                                      1.60                  354.83                                                                      
  BM blast (%)           75.6                                                                                        0.0                   91.4                                                                        
  Immunophenotype        Cortical T-ALL                                                                              NT                    Cortical T-ALL                                                              
  Chromosome             46,XY\[3\]                                                                                  NT                    No mitosis                                                                  
  *TCR* clonotype        Vγ9 + Jγ ^½^                                                                                Not detected          Vγ1-8 + Jγ 1/2                                                              
  2                      Age (yr)                                                                                    35                                                                                                35 (6 months later)
  WBC count (×10^9^/L)   14.93                                                                                       3.91                  5.43                                                                        
  BM blast (%)           87.2                                                                                        0.6                   41.0                                                                        
  Immunophenotype        Pro T-ALL                                                                                   NT                    Pro T-ALL                                                                   
  Chromosome             50,XY,+del(1)(p13p22),+del(4)(q31.1),+?7, +mar\[3\]/90\<4n≤,XXYY,-12,-22\[1\]/46,XY\[11\]   46,XY\[30\]           50,XY,+del(1)(p13p22),+del(4)(q31.1),+?7,+mar\[6\]/46,XY\[11\]              
  *TCR* clonotype        Not detected                                                                                Not detected          Not detected                                                                
  3                      Age (yr)                                                                                    21                                                                                                22 (10 months later)
  WBC count (×10^9^/L)   23.65                                                                                       13.01                 44.30                                                                       
  BM blast (%)           81.1                                                                                        1.8                   85.3                                                                        
  Immunophenotype        Pro T-ALL                                                                                   No detection of MRD   Medullary T-ALL                                                             
  Chromosome             46,XY,t(10;11)(p13;q21)\[17\]/46,XY\[3\]                                                    46,XY\[20\]           46,XY,t(10;11)(p13;q21)\[4\]/46,XY\[6\]                                     
  *TCR* clonotype        Vγ11+Jγ 1/2, Dδ+Jδ                                                                          Not detected          Vβ+Jβ                                                                       
  4                      Age (yr)                                                                                    19                                                                                                20 (14 months later)
  WBC count (×10^9^/L)   17.17                                                                                       3.62                  42.95                                                                       
  BM blast (%)           0.301                                                                                       0.7                   57.0                                                                        
  Immunophenotype        Medullary T-ALL                                                                             NT                    Cortical T-ALL                                                              
  Chromosome             46,XX\[4\]                                                                                  NT                    46,XX,?t(8;14)(p11.2;q32),?t(10;11)(p13;q21),i(17)(q10)\[3\]//46,XY\[21\]   
  *TCR* clonotype        Not detected                                                                                Not detected          Vγ1-8+Jγ 1/2, Vδ+Jδ                                                         

Abbreviations: BM, bone marrow; WBC, white blood cell; *TCR*, T-cell receptor; NT, not tested; T-ALL, T-acute lymphoblastic leukemia; MRD: minimal residual disease.

[^1]: ^\*^These two authors contributed equally to this work.
